Hence, restoring the ability of tumor associated pDCs to produce IFN-α in combination with TLR7/9-based immunotherapy with TGF-β and TNF-α antagonists can restore the antitumor immunity in breast cancer patients [55]. The gene discussed is TGFB1; the disease is neoplasm.